In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

Jien Wei Liu; Lih Shinn Wang; Yu Jen Cheng; Gwo Jong Hsu; Po Liang Lu; Yung Ching Liu; Chih Ming Chen; Chun Ming Lee; Wu Sun; Tsrang Neng Jang; Ping Cherng Chiang; Yin Ching Chuang; Hsiu Chen Lin; Zhi Yuan Shi; Hsiang Chi Kung; Cheng Hua Huang; Shih Ming Tsao; Chin Te Lu; Chun Hsing Liao; Po Ren Hsueh

doi:10.1016/S0924-8579(08)70026-8

In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

Jien Wei Liu, Lih Shinn Wang, Yu Jen Cheng, Gwo Jong Hsu, Po Liang Lu, Yung Ching Liu, Chih Ming Chen, Chun Ming Lee, Wu Sun, Tsrang Neng Jang, Ping Cherng Chiang, Yin Ching Chuang, Hsiu Chen Lin, Zhi Yuan Shi, Hsiang Chi Kung, Cheng Hua Huang^*, Shih Ming Tsao, Chin Te Lu, Chun Hsing Liao, Po Ren Hsueh

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

17 Scopus citations

Abstract

We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%), ciprofloxacin (75%), amikacin (69%), sulbactam (34%) and all four antibiotics (22%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71% to 82%. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 μg/mL (MIC₅₀ 2 μg/mL; MIC₉₀ 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9% and 93.1% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.

Original language	English
Pages (from-to)	S188-S191
Journal	International Journal of Antimicrobial Agents
Volume	32
Issue number	SUPPL. 3
DOIs	https://doi.org/10.1016/S0924-8579(08)70026-8
State	Published - 11 2008
Externally published	Yes

Keywords

Acinetobacter baumannii
Antibacterial drug resistance
Taiwan
Tigecycline

Access to Document

10.1016/S0924-8579(08)70026-8

Cite this

Liu, J. W., Wang, L. S., Cheng, Y. J., Hsu, G. J., Lu, P. L., Liu, Y. C., Chen, C. M., Lee, C. M., Sun, W., Jang, T. N., Chiang, P. C., Chuang, Y. C., Lin, H. C., Shi, Z. Y., Kung, H. C., Huang, C. H., Tsao, S. M., Lu, C. T., Liao, C. H., & Hsueh, P. R. (2008). In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. International Journal of Antimicrobial Agents, 32(SUPPL. 3), S188-S191. https://doi.org/10.1016/S0924-8579(08)70026-8

@article{c35c9ca3c18846bfa373e979eba9fe3c,

title = "In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan",

abstract = "We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44\%), ciprofloxacin (75\%), amikacin (69\%), sulbactam (34\%) and all four antibiotics (22\%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71\% to 82\%. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 μg/mL (MIC50 2 μg/mL; MIC90 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9\% and 93.1\% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.",

keywords = "Acinetobacter baumannii, Antibacterial drug resistance, Taiwan, Tigecycline",

author = "Liu, \{Jien Wei\} and Wang, \{Lih Shinn\} and Cheng, \{Yu Jen\} and Hsu, \{Gwo Jong\} and Lu, \{Po Liang\} and Liu, \{Yung Ching\} and Chen, \{Chih Ming\} and Lee, \{Chun Ming\} and Wu Sun and Jang, \{Tsrang Neng\} and Chiang, \{Ping Cherng\} and Chuang, \{Yin Ching\} and Lin, \{Hsiu Chen\} and Shi, \{Zhi Yuan\} and Kung, \{Hsiang Chi\} and Huang, \{Cheng Hua\} and Tsao, \{Shih Ming\} and Lu, \{Chin Te\} and Liao, \{Chun Hsing\} and Hsueh, \{Po Ren\}",

year = "2008",

month = nov,

doi = "10.1016/S0924-8579(08)70026-8",

language = "英语",

volume = "32",

pages = "S188--S191",

journal = "International Journal of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier B.V.",

number = "SUPPL. 3",

}

Liu, JW, Wang, LS, Cheng, YJ, Hsu, GJ, Lu, PL, Liu, YC, Chen, CM, Lee, CM, Sun, W, Jang, TN, Chiang, PC, Chuang, YC, Lin, HC, Shi, ZY, Kung, HC, Huang, CH, Tsao, SM, Lu, CT, Liao, CH & Hsueh, PR 2008, 'In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan', International Journal of Antimicrobial Agents, vol. 32, no. SUPPL. 3, pp. S188-S191. https://doi.org/10.1016/S0924-8579(08)70026-8

TY - JOUR

T1 - In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

AU - Liu, Jien Wei

AU - Wang, Lih Shinn

AU - Cheng, Yu Jen

AU - Hsu, Gwo Jong

AU - Lu, Po Liang

AU - Liu, Yung Ching

AU - Chen, Chih Ming

AU - Lee, Chun Ming

AU - Sun, Wu

AU - Jang, Tsrang Neng

AU - Chiang, Ping Cherng

AU - Chuang, Yin Ching

AU - Lin, Hsiu Chen

AU - Shi, Zhi Yuan

AU - Kung, Hsiang Chi

AU - Huang, Cheng Hua

AU - Tsao, Shih Ming

AU - Lu, Chin Te

AU - Liao, Chun Hsing

AU - Hsueh, Po Ren

PY - 2008/11

Y1 - 2008/11

N2 - We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%), ciprofloxacin (75%), amikacin (69%), sulbactam (34%) and all four antibiotics (22%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71% to 82%. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 μg/mL (MIC50 2 μg/mL; MIC90 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9% and 93.1% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.

AB - We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%), ciprofloxacin (75%), amikacin (69%), sulbactam (34%) and all four antibiotics (22%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71% to 82%. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 μg/mL (MIC50 2 μg/mL; MIC90 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9% and 93.1% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.

KW - Acinetobacter baumannii

KW - Antibacterial drug resistance

KW - Taiwan

KW - Tigecycline

UR - https://www.scopus.com/pages/publications/55649117054

U2 - 10.1016/S0924-8579(08)70026-8

DO - 10.1016/S0924-8579(08)70026-8

M3 - 文章

C2 - 19013353

AN - SCOPUS:55649117054

SN - 0924-8579

VL - 32

SP - S188-S191

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - SUPPL. 3

ER -

In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this